Open-Label, Randomized Controlled Trial of Pramipexole vs. Escitalopram to Treat Major Depressive Disorder (MDD) and MDD Comorbid with Mild Neurocognitive Disorder (MND) in People with HIV.

 

Key Inclusion Criteria:

1. Being living with HIV and on regular antiretroviral therapy (ART);

2. Being between 18 and 70 years old;

3. Having a diagnosis of Major Depressive Disorder (MDD);

4. Not having suicidal ideation, psychotic disorders, manic or hypomanic symptoms in the context of bipolar I or II disorder, or cyclothymic disorder or other Axis I diagnosis;

5. Not having rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus (SLE), dermatomyositis, ulcerative colitis, Crohn's disease, or other chronic inflammatory conditions.

​

Status: Expected Start Date: First Semester of 2026.